Gwendolyn Binder PhD

Gwendolyn Binder, Ph.D. is a prominent figure in the field of cell therapy and biotechnology, currently serving as the President of Science and Technology at Cabaletta Bio.14 Her career has been marked by significant contributions to the development of engineered T cell therapies for various diseases.

Professional Background

Dr. Binder joined Cabaletta Bio in February 2019 as one of the company's first employees.2 She quickly established herself as a key leader, setting up the preclinical, translational, manufacturing, and quality organizations.1 In her role, she is responsible for developing strategies to deliver competitive and transformative cellular therapeutics for patients with autoimmune diseases.1

Prior Experience

Before joining Cabaletta Bio, Dr. Binder held several notable positions:

• Chief Technology Officer at Adaptimmune Therapeutics plc, where she led the research team and established the U.S. arm of the company.12
• Director of Operations for the Translational Research Program at the University of Pennsylvania, where she advanced multiple Investigational New Drug (IND) applications for novel engineered T cell therapies.13
• Director of Scientific Affairs at VIRxSYS Corporation, supporting the development of the first clinical lentiviral vector used in humans for engineered T cell therapy for HIV.13

Education and Expertise

Dr. Binder earned her Ph.D. in Cellular and Molecular Medicine from Johns Hopkins University, where she studied viral immunology and translational research.13 She is recognized as an expert in T cell product development, translational research, and GMP manufacturing.5

Achievements and Recognition

Throughout her career, Dr. Binder has made significant contributions to the field:

• Authored over 30 publications in top international journals, including Science and Nature Medicine.34
• Played a key role in the development of Kymriah®, the CD19 CAR T cell therapy acquired by Novartis.14
• Contributed to the first human gene editing IND and multiple TCR engineered T cell therapy studies in oncology and HIV.14

Current Roles and Affiliations

In addition to her position at Cabaletta Bio, Dr. Binder:

• Serves on the Board of Directors of Instil Bio, a company developing tumor-infiltrating lymphocytes for cancer immunotherapy.16
• Is a member of the Scientific Advisory Board for Immatics N.V., which is developing engineered T cell immunotherapy for cancer.13

Dr. Binder is widely recognized as a leader in the biotechnology sector for her work in advancing novel T cell therapies for patients with serious diseases.34